Literature DB >> 17549376

Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.

Irina Fenic1, Klaus Steger, Christin Gruber, Christoph Arens, Joachim Woenckhaus.   

Abstract

PIK3CA, which encodes the catalytic subunit, p110-alpha, of phosphatidylinositol 3-kinase (PI3K), is implicated in the development and progression of numerous neoplasias including head and neck squamous cell carcinoma (HNSCC). In the present study, we investigated the occurrence of PIK3CA hot-spot mutations in exons 9 and 20, the genomic gain and amplification of PIK3CA, the expression of PIK3CA mRNA and the p110 alpha protein, as well as the expression of phosphorylated-Akt (pAkt) in 33 cases of HNSCC and compared the results with the clinicopathological data. No non-synonymous mutations were detected. PIK3CA copy number gain and amplification were found in 36.4 and 9% of the cases, respectively, whereas mRNA overexpression was observed in 48.5% of the cases. No correlations could be stated between DNA gain, DNA amplification and mRNA expression, either between DNA or mRNA status and p110 alpha expression. Direct associations were found between PIK3CA gain and lymph node metastases (p=0.025) and between mRNA expression and tumour stage (p=0.015). A strong correlation was detected between p110 alpha and pAkt expression (p<0.001). Concluding, PIK3CA could be an oncogene implicated in HNSCC development. However, our data suggest that amplifications or mutations of this gene seldom occur in HNSCC and that epigenetic events can play an important role in advanced tumour stages.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17549376

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  31 in total

Review 1.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Todd Waldman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

2.  Genetic association between PIK3CA gene and oral squamous cell carcinoma: a case control study conducted in Chongqing, China.

Authors:  Xiaoxiao Wan; Xian Li; Junyan Yang; Wei Lv; Qiming Wang; Ying Chen; Yong Li
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 3.  Dysregulated molecular networks in head and neck carcinogenesis.

Authors:  Alfredo A Molinolo; Panomwat Amornphimoltham; Cristiane H Squarize; Rogerio M Castilho; Vyomesh Patel; J Silvio Gutkind
Journal:  Oral Oncol       Date:  2008-09-19       Impact factor: 5.337

4.  Impact of warm ischemia on phosphorylated biomarkers in head and neck squamous cell carcinoma.

Authors:  Jacob I Tower; Mark W Lingen; Tanguy Y Seiwert; Alexander Langerman
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

5.  The determinants of head and neck cancer: Unmasking the PI3K pathway mutations.

Authors:  Fernanda S Giudice; Cristiane H Squarize
Journal:  J Carcinog Mutagen       Date:  2013-08-02

6.  Pathologic significance of AKT, mTOR, and GSK3β proteins in oral squamous cell carcinoma-affected patients.

Authors:  Flávia Sayuri Matsuo; Marília Ferreira Andrade; Adriano Mota Loyola; Sindeval José da Silva; Marcelo José Barbosa Silva; Sérgio Vitorino Cardoso; Paulo Rogério de Faria
Journal:  Virchows Arch       Date:  2018-04-30       Impact factor: 4.064

7.  Clinical significance of phosphatidyl inositol synthase overexpression in oral cancer.

Authors:  Jatinder Kaur; Meenakshi Sawhney; Siddartha Dattagupta; Nootan K Shukla; Anurag Srivastava; Ranju Ralhan
Journal:  BMC Cancer       Date:  2010-04-28       Impact factor: 4.430

8.  Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition.

Authors:  Natalie R Young; Jing Liu; Carolyn Pierce; Tai-Fen Wei; Tatyana Grushko; Olufunmilayo I Olopade; Wanqing Liu; Christine Shen; Tanguy Y Seiwert; Ezra E W Cohen
Journal:  Mol Oncol       Date:  2012-11-14       Impact factor: 6.603

9.  A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins.

Authors:  Stephen B Keysar; David P Astling; Ryan T Anderson; Brian W Vogler; Daniel W Bowles; J Jason Morton; Jeramiah J Paylor; Magdalena J Glogowska; Phuong N Le; Justin R Eagles-Soukup; Severine L Kako; Sarah M Takimoto; Daniel B Sehrt; Adrian Umpierrez; Morgan A Pittman; Sarah M Macfadden; Ryan M Helber; Scott Peterson; Diana F Hausman; Sherif Said; Ted H Leem; Julie A Goddard; John J Arcaroli; Wells A Messersmith; William A Robinson; Fred R Hirsch; Marileila Varella-Garcia; David Raben; Xiao-Jing Wang; John I Song; Aik-Choon Tan; Antonio Jimeno
Journal:  Mol Oncol       Date:  2013-04-04       Impact factor: 6.603

10.  Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors.

Authors:  Ann Marie Egloff; Jennifer Rubin Grandis
Journal:  J Oncol       Date:  2009-07-14       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.